Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 15;4:5.
doi: 10.1186/s40959-018-0031-4. eCollection 2018.

Do Current Approaches to Assessing Therapy Related Adverse Events Align With the Needs of Long-Term Cancer Patients and Survivors?

Free PMC article

Do Current Approaches to Assessing Therapy Related Adverse Events Align With the Needs of Long-Term Cancer Patients and Survivors?

Syril D Pettit et al. Cardiooncology. .
Free PMC article


The increasing efficacy of cancer therapeutics means that the timespan of cancer therapy administration is undergoing a transition to increasingly long-term settings. Unfortunately, chronic therapy-related adverse health events are an unintended, but not infrequent, outcome of these life-saving therapies. Historically, the cardio-oncology field has evolved as retrospective effort to understand the scope, mechanisms, and impact of treatment-related toxicities that were already impacting patients. This review explores whether current systemic approaches to detecting, reporting, tracking, and communicating AEs are better positioned to provide more proactive or concurrent information to mitigate the impact of AE's on patient health and quality of life. Because the existing tools and frameworks for capturing these effects are not specific to cardiology, this study looks broadly at the landscape of approaches and assumptions. This review finds evidence of increasing focus on the provision of actionable information to support long-term health and quality of life for survivors and those on chronic therapy. However, the current means to assess and support the impact of this burden on patients and the healthcare system are often of limited relevance for an increasingly long-lived survivor and patient population.

Keywords: Adverse effects; Cancer therapy; Patient reported outcomes; Survivorship.

Conflict of interest statement

Competing interestsSyril Pettit and Rebecca Kirch declare they have no competing interests. In addition to her role as a student at the UNC Gillings School of Global Public Health, Syril Pettit is also an employee of the non-profit Health and Environmental Sciences Institute (HESI). This work was not conducted as a term of her employment at HESI and she received no funding support from HESI. No conflicts are declared.


Fig. 1
Fig. 1
Schematic pathway linking cancer treatment, survivorship, adverse events, and quality of life (Original figure by Syril Pettit)
Fig. 2
Fig. 2
Summary of recommendations from literature review for improving adverse event data relevance in value frameworks

Similar articles

See all similar articles


    1. Lipshultz SE, Cochran TR, Franco VI, Miller TL. Treatment-related cardiotoxicity in survivors of childhood cancer. Nat Rev Clin Oncol [Internet]. 2013[cited 2018 Mar 26];10(12):697–710. Available from: - PubMed
    1. Lipshultz SE, Herman EH. Anthracycline cardiotoxicity: the importance of horizontally integrating pre-clinical and clinical research. Cardiovasc Res [Internet]. 2018[cited 2018 Mar 26];114(2):205–209. Available from: - PMC - PubMed
    1. Bansal N, Amdani S, Lipshultz ER, Lipshultz SE. Chemotherapy-induced cardiotoxicity in children. Expert Opin Drug Metab Toxicol [Internet]. 2017 [cited 2018 Mar 26];13(8):817–832. Available from: - DOI - PubMed
    1. Barac A, Murtagh G, Carver JR, Chen MH, Freeman AM, Herrmann J, et al. Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level. Vol. 65. Washington, DC: Elsevier USA; 2015. p. 2739–46. - PMC - PubMed
    1. Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, et al. Cardiovascular disease and breast Cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation [Internet]. 2018 Feb 20 [cited 2018 Mar 26];137(8):e30–e66. Available from: - PMC - PubMed

LinkOut - more resources